Radius Health Inc., of Waltham, Mass., reported data from two ongoing phase I studies of RAD1901, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. As of Oct. 7, 2016, 20 patients were treated in the RAD1901 phase Ib safety expansion cohort at the 400 mg dose.